GlobeNewswire Inc. · Sep 19, 2022
Celsion Corporation Announces Company Name Change to Imunon, Inc.
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines
CL
NASDAQ · CLSN
Imunon, Inc.
Healthcare · Biotechnology
$1.95
Down-$0.01 (-0.68%)
Updated Aug 24, 2026, 1:35 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 14.47M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 56.81K
- Avg. volume
- 60.97K
Price performance
CLSN price history
1M range · 0 trading sessions · Daily adjusted prices
CLSN does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest CLSN news
The latest Smart Investors Daily articles mentioning CLSN.
Stock researchCompany · Overview
CLSN research
Overview
Company profile and research snapshot.
Company profile
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 13, 2022 | HC Wainwright & Co. | Buy | — |
| Jul 16, 2020 | Oppenheimer | Perform | — |
| Nov 21, 2017 | Oppenheimer | Outperform | — |
| Oct 5, 2017 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Sep 12, 2022
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time. The presentation will available live and on-demand here.
GlobeNewswire Inc. · Sep 7, 2022
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will be held from September 12-14 with in-person participation held at the Lotte New York Palace Hotel.
GlobeNewswire Inc. · Sep 1, 2022
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
